Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 4 of 16
Sep 8, 2026The SPY003 result follows earlier phase 2 successes for SPY001 and SPY002, giving Spyre positive induction data for all three monotherapies in its Skyline platform. The strategic question now shifts from single-agent signal to whether combinations in Part B can produce a profile that stands out in a crowded ulcerative colitis market.
Sep 7, 2026The study applied six proteomic clocks to serum proteomes from a published phase 2a trial of rentosertib, an AI-designed TNIK inhibitor being developed for idiopathic pulmonary fibrosis and aging-related biology. All six clocks moved in the same direction, but the paper also highlights a central limitation for the field: biomarker shifts still need contextual biological analysis before they can be read as clean anti-aging effects.
Sep 5, 2026Pelacarsen was being watched as the first phase 3 attempt to prove that lowering lipoprotein(a) changes cardiovascular outcomes, not just a biomarker. Novartis now says that link was not shown in the overall study population, shifting attention to whether deeper suppression or different trial designs from Amgen and Eli Lilly can produce a different result.
Sep 4, 2026The patients did not move directly from xenograft to human transplant, with both returning to dialysis for months after the pig kidneys were removed. Even so, the reported outcome suggests the temporary use of gene-edited pig kidneys may not block a later conventional transplant, which is a meaningful operational signal for the field.
Sep 3, 2026The setback follows Ultragenyx’s recent approval for Genglycos and arrives just weeks before a PDUFA date for UX111 in Sanfilipo syndrome. The failed study also raises commercial and development questions for apazunersen beyond this single trial.
Sep 3, 2026In the 50-patient study, adults with celiac disease received TEV ’408 or placebo before a six-week daily gluten challenge. Teva said the antibody significantly reduced intestinal damage versus placebo and reported no safety signals, while signaling that additional phase 2 work is needed before a phase 3 program can proceed.
Sep 1, 2026The result is a setback on the headline data, and investors reacted by sending Alumis shares down 54% to below $10 in premarket trading. But the company is treating the trial as a patient-selection problem rather than a target failure, with plans to discuss an IFNGS-focused phase 3 design with the FDA.
Sep 1, 2026The two companies paused separate autoimmune CAR-T programs on the same day, each centered on autologous CD19-targeted candidates made with rapid manufacturing platforms. Novartis said its oncology program is not affected, while Bristol Myers said it is reviewing clinical data across zola-cel and aiming to resume enrollment as quickly as possible.
Aug 29, 2026One paper reports prime assembly, a method that uses prime editors to generate matching 3′-flaps on genomic DNA and donor DNA for precise replacement or insertion. A second paper describes donor-complementary prime editing, or DoPE, which pairs overhang double-stranded DNA donors with engineered guide RNAs to support one-step insertions up to 12.5 kilobases.
Aug 22, 2026The paper argues that exploratory analysis in single-cell omics still relies too heavily on visualization methods that require tuning and can be made to match prior expectations. Bonsai’s pitch is different: no tunable parameters, explicit handling of noise and a tree representation intended to preserve high-dimensional distances while supporting downstream analysis through Bonsai-scout.
Aug 20, 2026A Cell Press Blue review assembled findings from 350 previously published papers to argue that protein restriction and amino acid restriction may support healthy aging. Experts interviewed by STAT said the paper does not establish a human longevity benefit and could create risk if older adults, sedentary people, or people taking GLP-1 weight loss medicines respond by cutting protein too far.
Aug 17, 2026The Lugano trial tested duravyu against aflibercept in about 400 patients with wet age-related macular degeneration and did not meet its main endpoint on best corrected visual acuity after two years. EyePoint highlighted ad hoc and secondary analyses, while Mizuho called the overall result mixed and shifted attention to the upcoming Lucia readout.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.